ASX Penny Stocks To Watch In November 2024

In This Article:

The Australian market has experienced a downturn, with the ASX200 closing down 0.35% at 8266 points, as investors reacted to underwhelming Chinese stimulus measures and subsequent declines in commodity prices. In this context, identifying promising investment opportunities requires careful consideration of market dynamics and sector performance. While the term "penny stock" may seem outdated, it still signifies smaller or newer companies that can offer substantial value when backed by strong financials. We've identified three such stocks that combine financial robustness with potential for growth, providing investors with an opportunity to uncover hidden value in quality companies.

Top 10 Penny Stocks In Australia

Name

Share Price

Market Cap

Financial Health Rating

Embark Early Education (ASX:EVO)

A$0.76

A$138.53M

★★★★☆☆

LaserBond (ASX:LBL)

A$0.62

A$71.5M

★★★★★★

Helloworld Travel (ASX:HLO)

A$1.88

A$306.91M

★★★★★★

Austin Engineering (ASX:ANG)

A$0.545

A$350.38M

★★★★★☆

MaxiPARTS (ASX:MXI)

A$1.87

A$103.44M

★★★★★★

SHAPE Australia (ASX:SHA)

A$2.72

A$228.01M

★★★★★★

Navigator Global Investments (ASX:NGI)

A$1.60

A$813.53M

★★★★★☆

EZZ Life Science Holdings (ASX:EZZ)

A$2.94

A$127.05M

★★★★★★

Perenti (ASX:PRN)

A$1.165

A$1.08B

★★★★★★

Big River Industries (ASX:BRI)

A$1.34

A$114.39M

★★★★★☆

Click here to see the full list of 1,037 stocks from our ASX Penny Stocks screener.

We'll examine a selection from our screener results.

Algorae Pharmaceuticals

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Algorae Pharmaceuticals Limited is a pharmaceutical development company focused on the research and development of living cells technologies primarily in New Zealand, with a market cap of approximately A$11.81 million.

Operations: The company's revenue segment is derived entirely from its research and development efforts in living cell technologies, amounting to A$0.13 million.

Market Cap: A$11.81M

Algorae Pharmaceuticals, with a market cap of A$11.81 million, is pre-revenue and focused on living cells technologies. Despite its unprofitability and increased losses over the past five years, the company remains debt-free with sufficient cash runway for more than a year. Its short-term assets significantly exceed liabilities, providing financial stability in the near term. However, both management and board members are relatively inexperienced, potentially impacting strategic direction. The stock has experienced high volatility recently but hasn't diluted shareholder value over the past year. Recent results showed consistent net losses with minimal improvement in loss per share figures.